ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

China's lead in coronavirus vaccines raises concern as well as hope

Government-led medical sparks worries over safety and diplomatic clout

A nurse administers China's Sinovac vaccine, a potential vaccine for the coronavirus disease (COVID-19), to volunteer in Brazil.   © Reuters

TOKYO -- China has emerged as a leader in novel coronavirus vaccines, a development that will enhance it as a global power but also raises concerns over safety and the potential for Beijing to use its status in territorial disputes.

The country has nine vaccine candidates in clinical trials, including five in Phase 3, the final stage of the process toward approval. This achievement is the result of years of state-led research on infectious diseases. Last week, Chinese drugmaker CanSino Biologics announced it would conduct a Phase 3 trial in Saudi Arabia with 5,000 volunteers.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more